

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4191807/juan-a-pineda-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296 papers	6,452 citations	42 h-index	63 g-index
321 ext. papers	7,563 ext. citations	5.8 avg, IF	5.01 L-index

#	Paper	IF	Citations
296	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005 , 41, 779-89	11.2	214
295	Fast fibrosis progression between repeated liver biopsies in patients coinfectd with human immunodeficiency virus/hepatitis C virus. <i>Hepatology</i> , 2009 , 50, 1056-63	11.2	201
294	The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. <i>Clinical Infectious Diseases</i> , 2007 , 45, 969-74	11.6	155
293	Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. <i>Hepatology</i> , 2007 , 46, 622-30	11.2	154
292	Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfectd with HIV and hepatitis C virus. <i>Clinical Infectious Diseases</i> , 2010 , 51, 788-95	11.6	128
291	The Spanish HIV BioBank: a model of cooperative HIV research. <i>Retrovirology</i> , 2009 , 6, 27	3.6	124
290	Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. <i>Aids</i> , 2006 , 20, 49-57	3.5	121
289	Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. <i>Aids</i> , 2004 , 18, 767-74	3.5	119
288	Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 342-6	5.1	117
287	HCV epidemiology in high-risk groups and the risk of reinfection. <i>Journal of Hepatology</i> , 2016 , 65, S33-S45	5.4	111
286	Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfectd patients by simple non-invasive indexes. <i>Gut</i> , 2006 , 55, 409-14	19.2	97
285	A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. <i>Journal of Immunology</i> , 2012 , 188, 818-23	5.3	87
284	Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. <i>Clinical Infectious Diseases</i> , 2013 , 57, 465-8	11.6	76
283	Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfectd patients with compensated cirrhosis. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1646-53	11.6	69
282	High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. <i>Liver International</i> , 2008 , 28, 781-6	7.9	68
281	Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. <i>HIV Clinical Trials</i> , 2003 , 4, 337-46		66
280	Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfectd patients with compensated liver cirrhosis. <i>Hepatology</i> , 2012 , 56, 228-38	11.2	65

279	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2018 , 5, e23-e34	7.8	64
278	Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1274-82	11.6	62
277	Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?. <i>Aids</i> , 1992 , 6, 1499-503	3.5	62
276	Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2002 , 21, 775-81	5.3	58
275	Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. <i>Journal of Infectious Diseases</i> , 2008 , 197, 405-10	7	57
274	Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. <i>Lancet, The</i> , 1988 , 1, 1245-9	4.0	57
273	Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. <i>Clinical Infectious Diseases</i> , 2013 , 56, 143-50	11.6	56
272	Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1629-36	7	55
271	High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 1999 , 61, 766-9	3.2	55
270	Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. <i>Journal of Hepatology</i> , 1997 , 27, 25-9	13.4	52
269	Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1209-16	11.6	51
268	Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. <i>Journal of Hepatology</i> , 1993 , 17, 288-93	13.4	51
267	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013 , 27, 81-5	3.5	48
266	Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1365-73	5.1	48
265	Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993 , 12, 827-31	5.3	48
264	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018 , 155, 1120-1127.e4	13.3	47
263	Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. <i>Aids</i> , 2014 , 28, 1279-87	3.5	46
262	CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. <i>Clinical and Experimental Immunology</i> , 2000 , 119, 493-8	6.2	46

261	Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir. <i>Antiviral Therapy</i> , 2008 , 13, 429-438	1.6	46
260	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1333-1347	1.2	45
259	Diagnosis of infections with <i>Leishmania infantum</i> using PCR-ELISA. <i>Parasitology</i> , 2001 , 122, 607-15	2.7	45
258	Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 2419-22	9.7	44
257	Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. <i>Journal of Infection</i> , 2005 , 51, 195-200	18.9	42
256	Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 762-7	9.7	42
255	Transient Rebounds of Low-Level Viraemia among HIV-Infected Patients under Haart are Not Associated with Virological or Immunological Failure. <i>Antiviral Therapy</i> , 2002 , 7, 251-256	1.6	42
254	Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 1347-54	5.1	41
253	Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients. <i>Aids</i> , 2014 , 28, 1931-7	3.5	40
252	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015 , 71, 571-7	18.9	39
251	Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1467-70	11.6	39
250	Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 445-9	3.1	39
249	Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. <i>Antiviral Therapy</i> , 2010 , 15, 753-63	1.6	39
248	DETECTION OF LEISHMANIA INFANTUM KINETOPLAST DNA IN PERIPHERAL BLOOD FROM ASYMPTOMATIC INDIVIDUALS AT RISK FOR PARENTERALLY TRANSMITTED INFECTIONS: RELATIONSHIP BETWEEN POLYMERASE CHAIN REACTION RESULTS AND OTHER LEISHMANIA INFECTION MARKERS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004 , 70, 545-548	3.2	37
247	Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2011 , 25, 1415-20	3.5	36
246	Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2008 , 49, 916-22	13.4	36
245	Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1998 , 17, 167-70	5.3	35
244	Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 407-13	9.7	34

243	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012 , 56, 788-94	13.4	33
242	Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 915-21	1.6	31
241	Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. <i>Clinical Infectious Diseases</i> , 2001 , 32, 633-5	11.6	31
240	Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. <i>Journal of Hepatology</i> , 2019 , 71, 45-51	13.4	30
239	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2012 , 56, 1261-70	11.2	30
238	Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 839-846	1.6	30
237	HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. <i>HIV Clinical Trials</i> , 2017 , 18, 126-134		29
236	Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 905-11	2.2	29
235	Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naïve patients from 1989 to 1996. <i>Aids</i> , 1997 , 11, 1184-6	3.5	29
234	Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 4455-8	9.7	29
233	Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1566-76	7	29
232	Isolated renal mucormycosis in two AIDS patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1994 , 13, 430-2	5.3	28
231	HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014 , 28, 41-7	3.5	27
230	Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2204-11	5.1	27
229	Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. <i>PLoS ONE</i> , 2013 , 8, e68953	3.7	27
228	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
227	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 296-304	2.2	26
226	Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2013 , 27, 2541-9	3.5	26

225	Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfecting with human immunodeficiency virus and hepatitis C virus. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 675-80	5.3	26
224	Progression of liver fibrosis in patients coinfecting with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 417-9	5.1	26
223	Incidence of and Risk Factors for Insulin Resistance in Treatment-Naïve HIV-Infected Patients 48 Weeks after Starting Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 529-535	1.6	26
222	Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. <i>PLoS ONE</i> , 2013 , 8, e61992	3.7	25
221	The changing face of HIV/AIDS in treated patients. <i>Current HIV Research</i> , 2009 , 7, 365-77	1.3	25
220	Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 925-32	5.1	25
219	Leishmania infantum (Protozoa, kinetoplastida): transmission from infected patients to experimental animal under conditions that simulate needle-sharing. <i>Experimental Parasitology</i> , 2002 , 100, 71-4	2.1	25
218	Hepatitis C virus infection in sexually promiscuous groups. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990 , 9, 610-2	5.3	25
217	Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 1225-1236	1.6	25
216	FREQUENCY OF VISCERAL LEISHMANIASIS RELAPSES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004 , 70, 298-301	3.2	24
215	High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients. <i>Journal of Infection</i> , 2015 , 70, 624-30	18.9	23
214	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1012-1019	11.6	23
213	Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 714-9	3.4	23
212	Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 249-58	3.4	23
211	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011 , 25, 761-6	3.5	23
210	Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 801-7	2.2	23
209	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
208	Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 4027-9	9.7	22

207	Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 140-6	5.1	22
206	Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection. <i>Journal of Infectious Diseases</i> , 2013 , 207, 411-9	7	21
205	Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. <i>Gut</i> , 2009 , 58, 1654-60	9.2	21
204	Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. <i>Aids</i> , 2017 , 31, 493-500	3.5	20
203	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014 , 9, e95515	3.7	20
202	Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1401-8	11.6	20
201	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011 , 25, 1131-3	3.5	20
200	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/T/TA) in treatment-experienced, virologically-suppressed adults living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 68, 1162-7	10.8	19
199	Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions. <i>PLoS ONE</i> , 2014 , 9, e116226	3.7	19
198	A review of current anti-HCV treatment regimens and possible future strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 417-33	4	19
197	The high sensitivity of a PCR-ELISA in the diagnosis of cutaneous and visceral leishmaniasis caused by <i>Leishmania infantum</i> . <i>Annals of Tropical Medicine and Parasitology</i> , 2002 , 96, 669-77		19
196	Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 1998 , 26, 218-9	11.6	19
195	Detection of <i>Leishmania infantum</i> kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other <i>Leishmania</i> infection markers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004 , 70, 545-8	3.2	19
194	Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection. <i>Molecular Biology and Evolution</i> , 2014 , 31, 2402-14	8.3	18
193	Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection. <i>Aids</i> , 2013 , 27, 1697-706	3.5	18
192	Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2605-14	5.1	18
191	Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2838-42	5.1	18
190	Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon- α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. <i>Journal of Infectious Diseases</i> , 2012 , 206, 961-8	7	18

189	Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. <i>Journal of Hepatology</i> , 1999 , 31, 777-8	13.4	18
188	Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. <i>Journal of Infectious Diseases</i> , 1994 , 169, 267-73	7	18
187	Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2018 , 32, 1423-1430	3.5	17
186	IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015 , 29, 1895-7	3.5	17
185	Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2009 , 50, 684-92	13.4	17
184	Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1016-7	5.1	17
183	Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfecting patients with decompensated cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 1236-41	1.6	17
182	Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 449-56	3.4	17
181	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016 , 17, 766-773	2.7	17
180	Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2354-2362	11.6	17
179	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015 , 29, 1927-35	3.5	16
178	Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. <i>HIV Medicine</i> , 2014 , 15, 417-24	2.7	16
177	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1346-50	5.1	16
176	Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1719-26	11.6	16
175	Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 202-5	5.1	16
174	Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. <i>HIV Clinical Trials</i> , 2012 , 13, 61-9		16
173	MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. <i>PLoS ONE</i> , 2016 , 11, e0155245	3.7	16
172	Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 496-503	3.4	15

171	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. <i>Genes and Immunity</i> , 2014 , 15, 16-24	4.4	15
170	Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2011 , 12, 14-21	2.7	15
169	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011 , 12, 487-93	2.7	15
168	Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 793-6	5.1	15
167	Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2008 , 22, 923-30	3.5	15
166	Bone involvement and abscess formation by neutrophil-rich CD30+ anaplastic large-cell lymphoma mimicking skeletal infection in an AIDS patient. <i>Journal of Infection</i> , 2003 , 47, 73-6	18.9	15
165	Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. <i>Antiviral Therapy</i> , 2007 , 12, 523-529	1.6	15
164	HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. <i>Antiviral Therapy</i> , 2011 , 16, 585-9	1.6	14
163	Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. <i>HIV Medicine</i> , 2010 , 11, 439-47	2.7	14
162	HIV-1 infection among non-intravenous drug user female prostitutes in Spain. No evidence of evolution to pattern II. <i>Aids</i> , 1992 , 6, 1365-9	3.5	14
161	Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. <i>Antiviral Research</i> , 2018 , 150, 9-14	10.8	14
160	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015 , 120, 79-84	10.8	13
159	Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2017 , 31, 89-95	3.5	13
158	Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 2083-8	5.3	13
157	Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1291-5	11.6	13
156	Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. <i>Aids</i> , 2012 , 26, 1721-4	3.5	13
155	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 390-6	3.1	13
154	Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 178-83	5.1	13

153	Necrotizing granulomatous vasculitis in advanced HIV infection. <i>Journal of Infection</i> , 2003 , 47, 333-5	18.9	13
152	Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999 , 18, 733-6	5.3	13
151	Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. <i>Eurosurveillance</i> , 2019 , 24,	19.8	13
150	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
149	Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naïve and antiretroviral-experienced HIV-infected patients in Spain. <i>Aids</i> , 1998 , 12, 1015-20	3.5	13
148	Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. <i>Antiviral Therapy</i> , 2007 , 12, 1225-35	1.6	13
147	Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 699-706	3.4	12
146	Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2435-2443	5.1	12
145	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013 , 27, 2707-14	3.5	12
144	Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. <i>Clinical Infectious Diseases</i> , 2009 , 49, e84-91	11.6	12
143	Differences in virological response to peginterferon plus ribavirin in HIV-positive patients coinfecting with HCV subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 117-23	3.1	12
142	HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 46-8	5.3	12
141	HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. <i>Aids</i> , 2019 , 33, 1167-1174	3.5	12
140	Management of HCV-related end-stage liver disease in HIV-coinfected patients. <i>AIDS Reviews</i> , 2007 , 9, 131-9	1.5	12
139	Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelling by phylogenetic analysis. <i>PLoS ONE</i> , 2018 , 13, e0201268	3.7	11
138	Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 16-24	3.4	11
137	Leishmania spp infection in injecting drug users. <i>Lancet, The</i> , 2002 , 360, 950-1	4.0	11
136	Frequency of subclinical visceral leishmaniasis in HIV-1-infected patients in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996 , 15, 263-4	5.3	11

135	Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 839-46	1.6	11
134	Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study. <i>Zoonoses and Public Health</i> , 2017 , 64, e60-e64	2.9	10
133	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014 , 32, 447-58	0.9	10
132	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015 , 10, e0125080	3.7	10
131	Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015 , 61, 1503-11	11.2	10
130	Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 5185-96	5.9	10
129	LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. <i>Aids</i> , 2012 , 26, 1009-15	3.5	10
128	Evidence of increased risk for leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 354-7	5.3	10
127	Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in patients infected with HIV-1. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996 , 90, 383	2	10
126	The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. <i>PLoS ONE</i> , 2016 , 11, e0168265	3.7	10
125	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 597-608	0.9	10
124	Non-Alcoholic Fatty Liver Disease in HIV Infection. <i>AIDS Reviews</i> , 2017 , 19, 35-46	1.5	10
123	Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. <i>PLoS ONE</i> , 2019 , 14, e0221231	3.7	9
122	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013 , 32, 1427-35	5.3	9
121	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013 , 67, 59-64	18.9	9
120	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014 , 18, 700-8	2.1	9
119	Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. <i>Liver International</i> , 2012 , 32, 1031-2	7.9	9
118	Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfecting patients. <i>Aids</i> , 2010 , 24, 975-82	3.5	9

117	High rate of nonspecific anti-hepatitis C reactivity amongst homosexual men in comparison with that found in other sexually active groups and blood donors. Viral Hepatitis and AIDS Study Group. <i>Journal of Internal Medicine</i> , 1994 , 236, 73-7	10.8	9
116	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013 , 33, 33-38	0.9	9
115	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 409.e5-409.e8	9.5	8
114	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). <i>Clinical Microbiology and Infection</i> , 2015 , 21, 105.e1-5	9.5	8
113	High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. <i>Journal of Hepatology</i> , 2019 , 71, 876-888	13.4	8
112	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012 , 64, 204-11	18.9	8
111	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013 , 85, 1734-40	19.7	8
110	High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. <i>HIV Medicine</i> , 2017 , 18, 445-451	2.7	8
109	Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. <i>BMC Infectious Diseases</i> , 2015 , 15, 557	4	8
108	Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients. <i>Journal of Infection</i> , 2015 , 70, 680-3	18.9	8
107	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1351-3	5.1	8
106	Bilateral enophthalmos as a manifestation of HIV infection-related lipodystrophy. <i>HIV Medicine</i> , 2004 , 5, 448-9	2.7	8
105	Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine. <i>Aids</i> , 1998 , 12, 395-8	3.5	8
104	Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1995 , 14, 460-4	5.3	8
103	Isolated anti-HBc and hepatitis B virus occult infection. <i>Vox Sanguinis</i> , 1991 , 61, 140	3.1	8
102	Failure to detect silent HIV infection by polymerase chain reaction in subjects at risk for heterosexually transmitted HIV type 1 infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993 , 12, 663-7	5.3	8
101	Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. <i>Scientific Reports</i> , 2019 , 9, 12507	4.9	7
100	Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013 , 31, 424-9	0.9	7

99	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> , 2015 , 16, 72-80		7
98	High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015 , 33, 532-5	0.9	7
97	A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers. <i>Liver International</i> , 2014 , 34, 558-66	7.9	7
96	Low prevalence of occult HBV infection among HIV-infected patients in Southern Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012 , 30, 312-4	0.9	7
95	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012 , 9, 68	3.6	7
94	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013 , 27, 2715-24	3.5	7
93	Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. <i>HIV Clinical Trials</i> , 2008 , 9, 309-13		7
92	Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4 + T-cell counts. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 253-9	5.3	7
91	False-positive results of leishmanin skin test due to phenol-containing diluent. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2001 , 95, 173-4	2	7
90	Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood. <i>Liver</i> , 2001 , 21, 410-4		7
89	Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 315-6	9.7	7
88	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2810-2817	11.6	7
87	Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2019 , 33, 269-278	3.5	7
86	Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1929-36	5.3	6
85	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 104.e1-5	9.5	6
84	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. <i>Current HIV/AIDS Reports</i> , 2020 , 17, 6-17	5.9	6
83	Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. <i>Journal of Hepatology</i> , 2019 , 71, 1270-1272	13.4	6
82	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1837-48	4	6

81	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. <i>Infection</i> , 2013 , 41, 21-6	5.8	6
80	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017 , 35, 88-99	0.9	6
79	Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection. <i>Genes and Immunity</i> , 2015 , 16, 134-41	4.4	6
78	HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. <i>Antiviral Research</i> , 2012 , 95, 212-5	10.8	6
77	Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN- α for genotype 3 chronic hepatitis C in HIV-coinfected patients. <i>PLoS ONE</i> , 2012 , 7, e28115	3.7	6
76	Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 1225-32	5.3	6
75	Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. <i>AIDS Patient Care and STDs</i> , 2011 , 25, 395-402	5.8	6
74	Absence of HTLV-I and HTLV-II infection in prostitutes in the area of Seville, Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1991 , 10, 773-5	5.3	6
73	Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. <i>Antiviral Therapy</i> , 2017 , 22, 263-269	1.6	6
72	HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. <i>Pharmacogenomics Journal</i> , 2017 , 17, 551-555	3.5	5
71	KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. <i>Pharmacogenomics Journal</i> , 2017 , 17, 360-365	3.5	5
70	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 268-276	0.9	5
69	Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users. <i>Infection, Genetics and Evolution</i> , 2016 , 45, 20-25	4.5	5
68	No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014. <i>BMC Infectious Diseases</i> , 2016 , 16, 489	4	5
67	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , 2014 , 19, 407-14	1.6	5
66	Genetic variability at the TREX1 locus is not associated with natural resistance to HIV-1 infection. <i>Aids</i> , 2012 , 26, 1443-5	3.5	5
65	HAART and the liver: friend or foe?. <i>European Journal of Medical Research</i> , 2010 , 15, 93-6	4.8	5
64	Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 194-6	5.3	5

63	Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus-co-infected patients: still a role for liver biopsy?. <i>Aids</i> , 2004 , 18, 1746-8	3.5	5
62	Structural normalization of the lymphoid tissue in asymptomatic HIV-infected patients after 48 weeks of potent antiretroviral therapy. <i>Aids</i> , 2001 , 15, 2371-8	3.5	5
61	Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2109-e2116	11.6	5
60	Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPVIR SEG-HEP Cohort. <i>PLoS ONE</i> , 2016 , 11, e0148104	3.7	5
59	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017 , 18, 546-554	2.7	4
58	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 853-861	5.3	4
57	Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. <i>Journal of Infection</i> , 2019 , 79, 30-35	18.9	4
56	Host genetics. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 491-500	4.2	4
55	Recombinant EIA for anti-HIV testing is more specific than conventional EIA. <i>Vox Sanguinis</i> , 1988 , 54, 62-3	3.1	4
54	Rotative agitation RIA. A high sensitivity technique for hepatitis B surface antigen (HBsAg) determinations. <i>Journal of Hepatology</i> , 1986 , 3, 356-62	13.4	4
53	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4
52	Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 , 38, 127-131	0.9	4
51	Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 180-186	3.4	4
50	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. <i>Scientific Reports</i> , 2018 , 8, 14905	4.9	4
49	Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice. <i>HIV Clinical Trials</i> , 2018 , 19, 23-30		3
48	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014 , 68, 372-7	18.9	3
47	Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014 , 159, 3345-51	2.6	3
46	A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate. <i>Clinical Infectious Diseases</i> , 2014 , 58, 130-3	11.6	3

45	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 915-21	5.1	3
44	Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 87-91	5.1	3
43	Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain. <i>HIV Medicine</i> , 2021 , 22, 379-386	2.7	3
42	Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. <i>PLoS ONE</i> , 2016 , 11, e0155842	3.7	3
41	Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. <i>Aids</i> , 2020 , 34, 1497-1507	3.5	3
40	Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 48-54	3.4	3
39	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017 , 11, 188-198	8.8	2
38	Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1879-84	5.3	2
37	Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. <i>Scientific Reports</i> , 2020 , 10, 6736	4.9	2
36	Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. <i>International Journal of Infectious Diseases</i> , 2016 , 53, 46-51	10.5	2
35	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
34	HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. <i>Pharmacogenomics Journal</i> , 2017 , 17, 479-480	3.5	2
33	HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients. <i>PLoS ONE</i> , 2014 , 9, e99468	3.7	2
32	Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. <i>Lancet Infectious Diseases</i> , 2014 , 14, 13-14	25.5	2
31	Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. <i>PLoS ONE</i> , 2012 , 7, e48959	3.7	2
30	No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. <i>Antiviral Research</i> , 2012 , 95, 67-71	10.8	2
29	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005 , 42, 496-7; author reply 497	11.2	2
28	Low levels of HIV-1 plasma viral load in patients infected with HIV-1 subtype b and advanced immunosuppression. <i>Journal of Infection</i> , 2001 , 42, 4-7	18.9	2

27	HIV-1 progression in hepatitis-C-infected drug users. <i>Lancet, The</i> , 2001 , 357, 1362-3	4.0	2
26	Predictive value of the presence of P24 antigen in persons with antibodies to human immunodeficiency virus in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1989 , 8, 244-8	5.3	2
25	Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response. <i>Clinical Infectious Diseases</i> , 2021 , 72, e96-e102	11.6	2
24	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study.. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
23	Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals. <i>Journal of Infection</i> , 2017 , 74, 514-517	18.9	1
22	A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). <i>Liver International</i> , 2019 , 39, 1918-1926	7.9	1
21	Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection. <i>Scientific Reports</i> , 2019 , 9, 9054	4.9	1
20	Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability. <i>Infection, Genetics and Evolution</i> , 2019 , 73, 276-286	4.5	1
19	Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 2171-5	5.3	1
18	Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 1253-7	2.2	1
17	Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients. <i>HIV Clinical Trials</i> , 2009 , 10, 276-81		1
16	HIV-2 Infection in high-risk individuals in Spain. <i>Transfusion Science</i> , 1993 , 14, 167-172		1
15	HIV-1-Ag as the one marker in the early stage of HIV-1 infection. <i>Vox Sanguinis</i> , 1991 , 60, 241	3.1	1
14	Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. <i>PLoS ONE</i> , 2021 , 16, e0249036	3.7	1
13	Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 223-5	1.6	0
12	Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2375-2379	5.1	0
11	Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response. <i>Aids</i> , 2021 , 35, 2119-2127	3.5	0
10	Hepatitis C virus infection in Spain: Challenges in the track to elimination. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019 , 37, 219-221	0.1	

9	Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. <i>Antiviral Therapy</i> , 2015 , 20, 407-13	1.6
8	Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. <i>PLoS ONE</i> , 2015 , 10, e0143492	3.7
7	Influence of the combination of low-density lipoprotein receptor and interleukin 28B genotypes on lipid plasma levels in HIV/hepatitis C-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, e115-7	3.1
6	Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C. <i>Hepatology</i> , 2005 , 42, 498; author reply 498-9	11.2
5	Reply:. <i>Hepatology</i> , 2005 , 42, 497-497	11.2
4	Can the determination of HIV-1 Ag in serum be useful in identifying hemophiliac patients who end up developing AIDS?. <i>Vox Sanguinis</i> , 1989 , 56, 134-5	3.1
3	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020 , 21, 128-134	2.7
2	Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 878-886	3.4
1	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 597-608	0.1